Now in @JACCJournals by #HFC member @JavedButler1 et al.
A new study estimates the potential impact of recently approved cardiometabolic therapies and risk-based prevention strategies on the future burden of HF in the U.S. jacc.org/doi/10.1016/j.jchf.…
We were taught that Earth orbits the Sun in a closed circle. In reality, Earth has never returned to the same point in space once in 4.5 billion years.
Right now, the Sun is carrying Earth and every planet around the center of the Milky Way at 230 km/s (828,000 km/h), more than 18,000 kilometers every 80 seconds.
Because the Solar System is tilted 60.2° to the galactic plane and bobs up and down through the galactic disc roughly every 30 million years, the planets trace open 3D corkscrew helices across deep space rather than flat loops.
The last time the Sun stood where it stands today, one Galactic Year (230 million years) ago, the very first dinosaurs were only beginning to appear on Earth. Since forming 4.6 billion years ago, our Sun has completed only 20 laps.
Heading to AHA Scientific Sessions 2026 in Chicago?
I’d love to connect with colleagues interested in what’s next for finerenone in heart failure on Friday evening.
I’m extending an open invitation to investigators, clinicians, and research teams to join us at the University Club of Chicago to learn how the MOONRAKER program is moving forward—and explore opportunities to contribute to this work.
Building on FINEARTS-HF, three complementary phase 3 trials are addressing questions that matter in everyday clinical practice:
• REDEFINE-HF: Evaluating whether finerenone reduces cardiovascular death and first and recurrent HF events in patients hospitalized with acute heart failure and LVEF ≥40%. This will extend the evidence into the vulnerable period surrounding an HF hospitalization.
• CONFIRMATION-HF: Testing an early treatment strategy combining finerenone with an SGLT2 inhibitor across the EF spectrum, assessing whether this approach improves clinical outcomes and patient-reported symptoms compared with usual care following an HF hospitalization.
• FINALITY-HF: Evaluating finerenone in patients with HFrEF who are intolerant of or ineligible for steroidal MRAs, generating evidence on cardiovascular death, HF events, symptoms, and safety in a population with an important unmet treatment need.
Together, these studies will clarify where finerenone fits across HF populations and care settings, including its role in early combination therapy and in patients with limited treatment options.
I’m proud of our Saint Luke's Mid America Heart Institute team’s collaboration with Marc Bonaca, CPC Clinical Research, and investigators worldwide to advance this program.
Whether you’re already involved in MOONRAKER, interested in research collaboration, or simply want to learn more, please join us for an evening of conversation and connection.
📍 University Club of Chicago
76 East Monroe Street, Chicago
Message me for reception details and RSVP. I look forward to seeing you in Chicago!
Out now in @ESC_Journals from #HFC member @JavedButler1 et al.
This study evaluates the prognostic significance of residual moderate secondary mitral regurgitation in patients with heart failure after optimization of guideline-directed medical therapy. doi.org/10.1093/eschf/xvag25…
What if biomarker, functional and MACE outcomes are nested in one integrated cardiometabolic clinical trial design, without upsetting the alpha police?
Thank you @FaiezZANNAD, @JavedButler1, @ArunJSanyalVCU for an excellent #MOSAICMASH in DC!